Methylation, Mood and the Mind

Abstract:

As nutrition professionals increasingly serve clients with complex health concerns, integrating genomic science into practice offers a powerful tool for personalization. This article outlines how genetic polymorphisms (SNPs), methylation pathways, and nutrient cofactors impact neurotransmitter function, inflammation, and mood. Dietitians equipped with genomics training can identify root imbalances, guide targeted nutrient interventions, and collaborate effectively across multidisciplinary care teams to support mental health.

Introduction

Mental illness is one of the leading causes of disability in the United States, affecting approximately one in five US adults annually, with only 50% of those receiving treatment. There are also disproportionately higher rates observed in women and young adults aged 18 to 25 years.1 While standard approaches to treatment often include pharmacotherapy and psychotherapy, they may not always address underlying biochemical imbalances. Nutrigenomics—where nutrition meets genetics—empowers registered dietitians to provide precise, evidence-informed interventions based on an individual’s genetic makeup.

A signicant proportion of patients presenting with anxiety, depression, ADHD, or cognitive decline may have impaired methylation, oxidative stress, or detoxification issues that contribute to their symptoms.2-4 These disruptions can often be traced to single nucleotide polymorphisms (SNPs), nutrient defciencies, and environmental insults, which together impact gene expression through epigenetic mechanisms.2,5

The Role of Methylation in Mental Health

Methylation is a biochemical process central to neurotransmitter synthesis, detoxification, immune regulation, and DNA expression. Homocysteine (Hcy) metabolism can be used as a proxy for methylation status. Elevated Hcy levels, termed hyperhomocysteinemia (HHcy), are associated with neuroinflammation, oxidative stress, mitochondrial dysfunction, and cognitive impairment.4,6

SNPs in enzymes such as MTHFR, MTR, and MTRR impair remethylation of Hcy to methionine, reducing levels of S-adenosylmethionine (SAM), a critical methyl donor.3,7 This contributes to poor neurotransmitter function and an increased risk for psychiatric disorders, including depression, bipolar disorder, and schizophrenia.7,8

Key Methylation Nutrients and Functions:

• Folate (5-MTHF): Supports SAM production, DNA synthesis, and monoamine neurotransmitter synthesis. Low folate levels are correlated with major depressive disorder (MDD) and schizophrenia.9,10

• Vitamin B12: Works synergistically with folate in the remethylation of Hcy. SNPs in TCN2 can impair intracellular B12 transport, exacerbating deficiency even with adequate serum levels.11,12

• Vitamin B6: Required for the transsulfuration pathway, which metabolizes Hcy into cystathionine, and ultimately glutathione—a key antioxidant. Genetic variations in CBS or insufficient B6 can lead to HHcy and oxidative stress.4,13

• Choline & Betaine: Provide alternative methyl donors via the betaine-homocysteine methyltransferase (BHMT) pathway. PEMT variants can reduce phosphatidylcholine production and acetylcholine synthesis, affecting memory, cognition, and anxiety.2,14,15

Genetic Influences on Neurotransmitter Metabolism

Neurotransmitter synthesis, transport, and degradation are also heavily influenced by gene variants. A few of the heavy hitters:

• COMT Val158Met: A magnesium dependent enzyme that encodes catechol-O-methyltransferase, which degrades dopamine, norepinephrine, and epinephrine. The Met/Met genotype (AA) results in slow clearance and elevated catecholamines— potentially contributing to anxiety and an over-excitatory response. The Val/Val genotype (GG) leads to rapid degradation, potentially resulting in low motivation and depressive symptoms.16,17

• DRD2 Taq1A (ANKK1 gene): This polymorphism affects dopamine receptor density. Carriers of the T allele exhibit lower D2 receptor binding potential, increasing susceptibility to addiction, poor executive function, and mood instability.17-19

• MAOA and MAOB: These genes encode enzymes that degrade serotonin, dopamine, and norepinephrine. The MAOA T allele increases enzyme activity, lowering serotonin levels and increasing the risk for mood disorders, especially in males due to X-linked inheritance.20,21 MAOB activity also generates reactive oxygen species (ROS), contributing to oxidative stress in the brain.22 Slow MAO activity may contribute to aggression, while fast MAO activity may increase the risk of Parkinson’s due to oxidative stress and reduced dopamine levels.22

When COMT, MAOA, and DRD2 polymorphisms co-exist, the risk for psychiatric disorders and addictive behaviors increases significantly.17 Dietitians can use this information to better understand patient behavior, medication sensitivity, and tailor nutrition plans to support neurotransmitter balance.

Environmental and Epigenetic Modifiers

Epigenetics refers to changes in gene expression not caused by changes in the DNA sequence, often modi able by environment and lifestyle. Prenatal and early-life exposures have lasting effects on mental health through epigenetic programming.2,23 There are many variables involved in the manifestation of mental health symptoms, and environmental exposures must also be considered. Examples include:

• Bisphenol A (BPA): A known endocrine disruptor, BPA exposure in utero is associated with lower vocabulary scores in boys, ADHD, ASD, and anxiety.24,25

• Early-life stress: Animal models show that early maternal separation leads to hypomethylation of BDNF and increased oxidative stress, resulting in autistic-like behaviors, particularly in boys.2 Allan Schore’s work (2017) described infant boys’ particular sensitivity to stressors: attachment trauma and endocrine disruption due to the slower development of the right brain than girls and subsequent increased risk for ASD, ADHD, etc.10

• Heavy metals: Lead, mercury, and arsenic can disrupt neurotransmitter metabolism via increased oxidative stress and straining methylation pathways.26

• Medications: Many medications used to manage anxiety, depression, schizophrenia, bipolar, etc, deplete nutrients that are needed to manage mental health. Oral contraceptives have also been shown to deplete crucial nutrients and impact oxidative stress enzymes like catalase, glutathione peroxidase, and superoxide dismutase.27-29

Epigenetic disruptions like these may alter the function of key genes like BDNF, essential for synaptic neuroplasticity, memory, and mood regulation.5,30

Vagus Nerve, HRV, and Dietary Interventions

The vagus nerve plays a pivotal role in parasympathetic nervous system function and in inflammatory regulation. Low vagal tone (which can be assessed by heart rate variability, or HRV) is correlated with depression, anxiety, and poor stress resilience.31,32

Dietitians can support vagal tone by recommending:

• Polyphenol-rich foods (eg, olive oil, cruciferous vegetables, green tea, berries)

• Omega-3 fatty acids (eg, fish oil, flaxseed)

• Mind-body practices like yoga, deep breathing, vagus nerve activation, and cold exposure

• Gut microbiome support (prebiotic and probiotic foods)

These strategies not only support vagal tone but reduce systemic inflammation and oxidative stress, further supporting mood regulation.

Translating Genomics into Clinical Practice

Dietitians can use genomic insights to

• personalize nutrient recommendations based on biochemistry pathways that might be manifesting in mental health challenges;

• identify individuals at risk for mental health issues due to impaired detoxification or methylation;

• monitor methylation-related biochemical markers such as Hcy, B12, folate (RBC), and methylmalonic acid (MMA); and

• improve adherence and outcomes through targeted precision guidance and interdisciplinary care.

Evidence-Based Applications:

• Folate and B12 supplementation has been shown to improve depressive symptoms in older adults and reduce cognitive decline when given over two years.33,34

• Sulforaphane, a broccoliderived Nrf2 activator, promotes BDNF expression and has antidepressant-like e ects in animal models.35,36

• Ashwagandha supports cortisol regulation and reduces anxiety, and may optimize hormone levels. Utilize as a tea before supplementing.37,38

• Castor oil packs have been used adjunctively for detoxi cation and reducing in ammation in clinical settings.39-41 They are one of the best non-food, non-supplement interventions with results for clients in sleep, digestion, bowel movements, hormones, chronic pain, or autoimmune symptoms.

Case Studies

Case 1 – Female, age 36:

History of PTSD, bipolar disorder, OCD, ADHD, PCOS, and obesity. Genetic testing revealed slow MAOA, CYP1B1, CYP17A1, IL-6, and GSTM1 deletion impacting detoxification pathways, including clearing excess neurotransmitters and hormones. Functional testing showed very high glutamate levels creating an excitatory response. Years of psychiatric medications led to nutrient depletions (B12, folate, glutathione). Intervention focused on B-vitamin repletion, magnesium and sulforaphane supplementation, vagus nerve activation (eg, singing, breath work), and detoxification-focused nutrition (protein, B vitamins, and minerals like sulfur, magnesium, selenium, zinc, manganese, and molybdenum). Outcomes included improved sleep, reduced anxiety, and weight loss.

Case 2 – Male, age 58:

High supplement use, childhood trauma from the death of his mother from breast cancer at age 45, GERD, anxiety, depression, high stress, persistent migraines, food sensitivities, and poor sleep. SNPs revealed slow COMT, CYP1B1, DAO, and PEMT, resulting in impaired histamine clearance. Simpli ed supplement plan included magnesium glycinate, phosphatidylcholine, and omega3s. Food-first approach emphasized protein to support neurotransmitter production, choline, and polyphenol intake. Lifestyle coaching focused on stress management to “work on purpose” and “rest on purpose,” enjoyable movement that is sustainable, topical castor oil packs, and vagal engagement. Client was relieved to reduce supplement burden and to have guidance that had the best return on investment of time and resources.

Conclusion: A Call to Action for Dietitians

Genomic testing is no longer niche—it is an essential tool for advanced nutrition assessment. RDNs can bridge the gap between biochemical individuality and evidence-based interventions. By understanding how genes inuence nutrient needs and neurobiology, dietitians are uniquely positioned to guide patients toward mental wellness through personalized nutrition.

Continued education in nutrigenomics will enable dietitians to

• enhance diagnostic accuracy,

• improve patient engagement and compliance,

• support interdisciplinary mental health care teams, and

• optimize outcomes using food as a foundational therapy.

References

1. 2022 NSDUH annual national report. Substance Abuse and Mental Health Services Administration. November 13, 2023. Accessed July 24, 2025. https:// www.samhsa.gov/data/report/2022nsduh-annual-national-report

2. Bekdash RA. Epigenetics, nutrition, and the brain: improving mental health through diet. Int J Mol Sci. 2024;25(7):4036. doi:10.3390/ ijms25074036

3. Nazki FH, Sameer AS, Ganaie BA. Folate: metabolism, genes, polymorphisms and the associated diseases. Gene. 2014;533(1):11-20. doi:10.1016/j.gene.2013.09.063

4. Al Mutairi F. Hyperhomocysteinemia: clinical insights. J Cent Nerv Syst Dis. 2020;12:1179573520962230. doi:10.1177/1179573520962230

5. Fungaro Rissatti L, Wilson D, PalaceBerl F, et al. BDNF methylation associated with stress in women: novel insights in epigenetics and in ammation. Brain Behav Immun Health. 2024;42:100900. doi:10.1016/j.bbih.2024.100900

6. Cordaro M, Siracusa R, Fusco R, Cuzzocrea S, Di Paola R, Impellizzeri D. Involvements of hyperhomocysteinemia in neurological disorders. Metabolites. 2021;11(1):37. doi:10.3390/ metabo11010037

7. Zhang Y, Yang L, Gai C, et al. Association between variants of MTHFR genes and psychiatric disorders: a metaanalysis. Front Psychiatry. 2022;13:976428. doi:10.3389/fpsyt.2022.976428

8. Miasko MH, Smail SW, Karim AY, et al. Association study of polymorphisms at A66G (rs1801394) of MTRR gene and autism spectrum disorders in a Kurdish population. Gene Reports. 2020;21:100949. doi:10.1016/j. genrep.2020.100949

9. Zheng W, Li W, Qi H, et al. Adjunctive folate for major mental disorders: a systematic review. J A ect Disord. 2020;267:123-130. doi:10.1016/j. jad.2020.01.096

10. Rajen N, Velure HW, Johnsen E, Bjørke-Monsen A. Impaired folate status in patients with mental disorders. Acta Neuropsychiatr. 2025;37:e11. doi:10.1017/ neu.2025.1

11. Sangle P, Sandhu O, Aftab Z, Anthony AT, Khan S. Vitamin B12 supplementation: preventing onset and improving prognosis of depression. Cureus J Med Sci. 2020;12(10):e11169. doi:10.7759/ cureus.11169

12. Stanisawska-Sachadyn A, Woodside JV, Sayers CM, et al. Transcobalamin (TCN2) 776C>G polymorphism a ects homocysteine concentrations among subjects with low vitamin B12 status. Eur J Clin Nutr. 2010;64(11):1338-1343. doi:10.1038/ejcn.2010.157

13. Almeida MR, Mabasa L, Crane C, et al. Maternal vitamin B6 de cient or supplemented diets on expression of genes related to GABAergic, serotonergic, or glutamatergic pathways in hippocampus of rat dams and their o spring. Mol Nutr Food Res. 2016;60(7):1615-1624. doi:10.1002/ mnfr.201500950

14. Liu Y, Zhang H, Ju G, et al. A study of the PEMT gene in schizophrenia. Neurosci Lett. 2007;424(3):203-206. doi:10.1016/j. neulet.2007.07.038

15. Bjelland I, Tell GS, Vollset SE, Konstantinova S, Ueland PM. Choline in anxiety and depression: the Hordaland Health Study. Am J Clin Nutr. 2009;90(4):1056-1060. doi:10.3945/ ajcn.2009.27493

16. Taylor S. Association between COMT Val158Met and psychiatric disorders: a comprehensive meta‐analysis. Am J Med Genet B Neuropsychiatr Genet. 2018;177(2):199-210. doi:10.1002/ ajmg.b.32556

17. Kaminskaite M, Jokubka R, Janaviciute J, et al. Epistatic e ect of Ankyrin repeat and kinase domain containing 1 – Dopamine receptor D2 and catechol-o-methyltransferase single nucleotide polymorphisms on the risk for hazardous use of alcohol in Lithuanian population. Gene. 2021;765:145107. doi:10.1016/j.gene.2020.145107

18. Gluskin BS, Mickey BJ. Genetic variation and dopamine D2 receptor availability: a systematic review and meta-analysis of human in vivo molecular imaging studies. Transl Psychiatry. 2016;6(3):e747. doi:10.1038/ tp.2016.22

19. Zhang L, Hu L, Li X, Zhang J, Chen B. The DRD2 rs1800497 polymorphism increase the risk of mood disorder: evidence from an update metaanalysis. J A ect Disord. 2014;158:71-77. doi:10.1016/j.jad.2014.01.015

20. Liu Z, Huang L, Luo X, Wu L, Li M. MAOA variants and genetic susceptibility to major psychiatric disorders. Mol Neurobiol. 2016;53(7):4319-4327. doi:10.1007/s12035-015-9374-0

21. Heger J, Szabados T, Brosinsky P, et al. Sex di erence in cardioprotection against acute myocardial infarction in MAO-B knockout mice in vivo. Int J Mol Sci. 2023;24(7):6443. doi:10.3390/ ijms24076443

22. Naoi M, Riederer P, Maruyama W. Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression. J Neural Transm (Vienna). 2016;123(2):91-106. doi:10.1007/s00702014-1362-4

23. Schore AN. All our sons: the developmental neurobiology and neuroendocrinology of boys at risk. Infant Ment Health J. 2017;38(1):15-52. doi:10.1002/imhj.21616

24. Jensen TK, Mustieles V, Bleses D, et al. Prenatal bisphenol A exposure is associated with language development but not with ADHD-related behavior in toddlers from the Odense child cohort. Environ Res. 2019;170:398-405. doi:10.1016/j.envres.2018.12.055

25. Costa HE, Cairrao E. E ect of bisphenol A on the neurological system: a review update. Arch Toxicol. 2023;98(1):1-73. doi:10.1007/s00204-02303614-0

26. Fu Z, Xi S. The e ects of heavy metals on human metabolism. Toxicol Mech Methods. 2019;30(3):167-176. doi:10.1080 /15376516.2019.1701594

27. Fallah S, Valinejad Sani F, Firoozrai M. E ect of contraceptive pills on the activity status of the antioxidant enzymes glutathione peroxidase and superoxide dismutase in healthy subjects. Contraception. 2011;83(4):385-389. doi:10.1016/j. contraception.2010.07.026

28. Webb JL. Nutritional e ects of oral contraceptive use: a review. J Reprod Med. 1980;25(4):150-156.

29. Clapp Organski A, Fuller KNZ, Thyfault JP, Cross T-WL. Gut microbial and metabolic perturbations associated with oral contraceptives. 2022. https://centers.purdue.edu/ microbiome/wp-content/uploads/ sites/4/2022/05/2022-PAMS-SymposiumProgram-Final_9-May.pdf

30. Zheleznyakova GY, Cao H, Schiöth HB. BDNF DNA methylation changes as a biomarker of psychiatric disorders: literature review and open access database analysis. Behav Brain Funct. 2016;12(1):17. doi:10.1186/s12993-0160101-4

31. Grote V, Levnajić Z, Pu H, et al. Dynamics of vagal activity due to surgery and subsequent rehabilitation. Front Neurosci. 2019;13:1116. doi:10.3389/ fnins.2019.01116

32. Pinna T, Edwards DJ. A systematic review of associations between interoception, vagal tone, and emotional regulation: potential applications for mental health, wellbeing, psychological exibility, and chronic conditions. Front Psychol. 2020;11:1792. doi:10.3389/ fpsyg.2020.01792

33. Skarupski KA, Tangney C, Li H, Ouyang B, Evans DA, Morris MC. Longitudinal association of vitamin B-6, folate, and vitamin B-12 with depressive symptoms among older adults over time. Am J Clin Nutr. 2010;92(2):330-335. doi:10.3945/ajcn.2010.29413

34. Walker JG, Batterham PJ, Mackinnon AJ, et al. Oral folic acid and vitamin B-12 supplementation to prevent cognitive decline in communitydwelling older adults with depressive symptoms—the Beyond Ageing Project: a randomized controlled trial. Am J Clin Nutr. 2012;95(1):194-203. doi:10.3945/ ajcn.110.007799

35. Yao W, Lin S, Su J, et al. Activation of BDNF by transcription factor Nrf2 contributes to antidepressant-like actions in rodents. Transl Psychiatry. 2021;11(1):140. doi:10.1038/s41398-02101261-6

36. Houghton CA. Sulforaphane: its “coming of age” as a clinically relevant nutraceutical in the prevention and treatment of chronic disease. Oxid Med Cell Longev. 2019;2019:2716870. doi:10.1155/2019/2716870

37. Wiciński M, Fajkiel-Madajczyk A, Kurant Z, et al. Can ashwagandha bene t the endocrine system?—a review. Int J Mol Sci. 2023;24(22):16513. doi:10.3390/ ijms242216513

38. Salve J, Pate S, Debnath K, Langade D. Adaptogenic and anxiolytic e ects of ashwagandha root extract in healthy adults: a double-blind, randomized, placebo-controlled clinical study. Cureus. 2019;11(12):e6466. doi:10.7759/ cureus.6466

39. Arslan GG, Eşer İ. An examination of the e ect of castor oil packs on constipation in the elderly. Complement Ther Clin Pract. 2011;17(1):58-62. doi:10.1016/j.ctcp.2010.04.004

40. Vieira C, Evangelista S, Cirillo R, et al. E ect of ricinoleic acid in acute and subchronic experimental models of in ammation. Mediators Inamm. 2000;9(5):223-228. doi:10.1080/09629350020025737

41. Alookaran J, Tripp J. Castor oil. In: StatPearls. StatPearls Publishing; May 24, 2024. Accessed April 3, 2025. https://www.ncbi.nlm.nih.gov/books/ NBK551626/